Advanced Search

    Technical Analysis for PRAX - Praxis Precision Medicines, Inc.

    Grade Last Price % Change Price Change
    C 4.34 -3.34% -0.15
    PRAX closed down 3.34 percent on Wednesday, February 8, 2023, on 77 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: Feb 27
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Down
    Historical PRAX trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Older End-of-Day Signals for PRAX ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Possible NR7 about 8 hours ago
    Possible Inside Day about 8 hours ago
    60 Minute Opening Range Breakout about 11 hours ago
    20 DMA Support about 12 hours ago
    Down 3% about 13 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    Praxis Precision Medicines, Inc. Description

    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Neuroscience Precision Medicine Epilepsy Central Nervous System Disorders Nervous System Disorders Major Depressive Disorder Depression Depressive Disorder Huntington's Disease Oligonucleotide Treatment Of Major Depressive Disorder Spinal Muscular Atrophy Neuron Antisense RNA Essential Tremor Receptor Positive Ionis Perimenopausal Depression

    Is PRAX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Feb 7 Praxis Precision Medicines GAAP EPS of -$0.87 misses by $0.08
    Feb 7 Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
    Jan 13 US Stocks Edge Lower; Bank of America Profit Tops Views
    Dec 14 Praxis Precision Medicines and UCB collaborate for epilepsy research
    Dec 13 Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
    Nov 28 Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
    Nov 28 Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
    Nov 9 Praxis Precision Medicines GAAP EPS of -$0.96 misses by $0.04
    Nov 9 Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
    Nov 9 Positive week for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional investors who lost 89% over the past year
    See more PRAX news...

    Indicators

    Indicator Value
    52 Week High 14.25
    52 Week Low 1.48
    Average Volume 1,113,978
    200-Day Moving Average 3.71
    50-Day Moving Average 3.09
    20-Day Moving Average 4.29
    10-Day Moving Average 4.67
    Average True Range 0.40
    RSI 58.51
    ADX 56.0
    +DI 27.29
    -DI 12.76
    Chandelier Exit (Long, 3 ATRs) 4.05
    Chandelier Exit (Short, 3 ATRs) 3.57
    Upper Bollinger Bands 5.44
    Lower Bollinger Band 3.14
    Percent B (%b) 0.52
    BandWidth 53.61
    MACD Line 0.46
    MACD Signal Line 0.54
    MACD Histogram -0.0771
    Fundamentals Value
    Market Cap 166.06 Million
    Num Shares 38.3 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 95.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.60
    Resistance 3 (R3) 4.61 4.54 4.56
    Resistance 2 (R2) 4.54 4.47 4.53 4.54
    Resistance 1 (R1) 4.44 4.43 4.40 4.43 4.53
    Pivot Point 4.36 4.36 4.34 4.36 4.36
    Support 1 (S1) 4.26 4.29 4.23 4.25 4.15
    Support 2 (S2) 4.19 4.25 4.18 4.14
    Support 3 (S3) 4.09 4.19 4.12
    Support 4 (S4) 4.08